Immune Repertoire Sequencing Market size is set to reach USD 3 Billion by the end of 2035, growing at a CAGR of 7% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of immune repertoire sequencing was around USD 1 Billion. The market is primarily driven by the escalating government encouragement for pharmacogenomics-based drug recovery. Furthermore, growth in multiple therapeutic areas such as cardiology, pain management, oncology, infectious diseases, and others is estimated to boost the market expansion in the projected period.
Additionally, the industry has been driven by many organizations seeking answers to biomarkers of the immune system. Mergers and acquisitions are also driving the market. More collaboration, acquisition, and agreement among the market players are majorly contributing to the industry growth. In order to produce effective and creative immunotherapies ArcherDX and Ambry Genetics joined hands in March 2018.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023 – 2035 |
|
CAGR |
~7% |
|
Base Year Market Size |
~USD 1 billion |
|
Forecast Year Market Size |
~USD 3 billion |
|
Regional Scope |
|
Product Type (Instruments, Assay Kits)
The assay kits segment in the immune repertoire sequencing market is set to witness the highest revenue share of 60% by the end of 2035. Assay kits are distributed into TCR kits and BCR kits. The TCR is a significant part of the human adaptive immune system. With the help of this system pathogenic are being identified, recalled, and destroyed. Therefore, various companies are signing agreements and merging in order to offer repertoire sequencing kits for a specific type of immunotherapy.
End User (Pharmaceutical Companies, Research Institutes, Diagnostic Labs)
The immune repertoire sequencing market from the pharmaceutical segment is poised to experience the largest demand throughout the projected period. Pharmaceutical companies primarily use immune repertoire sequencing to recognize and validate potential therapeutic targets. By knowing the functionality and diversity of immune cells and receptors they can make drugs that can modulate immune responses.
Moreover, pharmaceutical companies often collaborate with research organizations, academic institutions, and sequencing technology providers for advanced immune repertoire sequencing research.
Our in-depth analysis of the global market includes the following segments:
|
Product Type |
|
|
Application |
|
|
End User |
|
North American Market Forecast
The immune repertoire sequencing market in North America is projected to occupy the largest share over the period between 2023 – 2035. This can be ascribed to the high health spending, and strong presence of market players in the region, especially in the United States and Canada. According to the Centers for Medicare & Medicaid Services (CMS), health spending in the United States grew by 9.7% in 2020, reaching a value of USD 4.1 trillion, or USD 12,530 per person. The market is also anticipated to grow with escalating demand for immunotherapy for cancer and other infectious diseases.
APAC Market Statistics
The immune repertoire sequencing market in the Asia Pacific region is estimated to observe noteworthy market demand throughout the estimated period. This can be attributed on the back of the increasing number of international collaborations for immune repertoire sequencing in the region.
In addition, the focus of countries, namely China and Japan, on the integration of new technologies in the healthcare sector is also expected to drive market growth significantly in the coming years.
Author Credits: Smruti Ranjan, Rajrani Baghel
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?